Clinical trial · Observational
An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade
Velcade (Bortezomib for Injection) Observational Study
NCT01675245CI-TRIAL-00014826completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to acquire information on the usage, effectiveness, safety, and levels of health care resource utilization associated with Velcade therapy in recurrent and refractory multiple myeloma patients who are initiating Velcade and various combination therapies within the approved indication in a naturalistic setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Velcade
- description
- Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
- interventionNames
- Drug: No intervention
Primary outcomes (29)
- measure
- Information on treatment sequence for Velcade therapy
- timeFrame
- Baseline (Day -1) to Day 21
- description
- Treatment sequence or the line of therapy will be considered on Velcade utilization.
- measure
- Information on dosage of Velcade
- timeFrame
- Baseline to Day 21
- description
- Dosage of Velcade will be considered on Velcade utilization. The unit of dosage will be milligram per square meter body surface area.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must give informed consent in agreement with local legislation * Must not have any contraindication listed in package insert Exclusion Criteria: * Patients currently participating in another investigational study of Velcade or any other medication * Patients with severe hepatic or renal impairment * Patients with platelet count below 25000/μl * Patients who are considered disqualified for the study by the investigators
References
Publications (1)
- DERIVEDLin M, Hou J, Chen W, Huang X, Liu Z, Zhou Y, Li Y, Zhao T, Wang L, Wu KW, Shen Z. Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients. Adv Ther. 2014 Oct;31(10):1082-94. doi: 10.1007/s12325-014-0159-z. Epub 2014 Oct 21. PMID 25331616